相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dosing equation for tacrolimus using genetic variants and clinical factors
Chaitali Passey et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic leukemia
Louise Borst et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Association of the CYP3A5 polymorphism (6986G>A) with blood pressure and hypertension
Bo Xi et al.
HYPERTENSION RESEARCH (2011)
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
Jesus Garcia-Donas et al.
LANCET ONCOLOGY (2011)
Increased Risk of Vincristine Neurotoxicity Associated With Low CYP3A5 Expression Genotype in Children With Acute Lymphoblastic Leukemia
Akinbode Egbelakin et al.
PEDIATRIC BLOOD & CANCER (2011)
Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I
Christine E. Staatz et al.
CLINICAL PHARMACOKINETICS (2010)
Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa
Corine Ekhart et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Higher tacrolimus trough levels on days 2-5 post-renal transplant are associated with reduced rates of acute rejection
C. M. O'Seaghdha et al.
CLINICAL TRANSPLANTATION (2009)
Genetic polymorphisms in estrogen metabolism and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians
Naoki Shimada et al.
JOURNAL OF HUMAN GENETICS (2009)
CYP3A5 and ABCB1 genes and hypertension
Murielle Bochud et al.
PHARMACOGENOMICS (2009)
Statin regulation of CYP3A4 and CYP3A5 expression
Maria Alice Vieira Willrich et al.
PHARMACOGENOMICS (2009)
Trough Tacrolimus Concentrations in the First Week After Kidney Transplantation Are Related to Acute Rejection
Alberto M. Borobia et al.
THERAPEUTIC DRUG MONITORING (2009)
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
Ulrich M. Zanger et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2008)
Influence of CYP3A5 Genetic Polymorphism on Tacrolimus Daily Dose Requirements and Acute Rejection in Renal Graft Recipients
Lina Quteineh et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2008)
CYP3A5*3A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia
Maria Alice V. Willrich et al.
CLINICA CHIMICA ACTA (2008)
Frequencies of CYP3A5 genotypes and haplotypes in a Korean population
S. Y. Park et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2008)
CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients
L. Renders et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Genotyping of CYP3A5 polymorphisms among Bulgarian patients with sporadic colorectal cancer and controls
Darinka Todorova Petrova et al.
ONKOLOGIE (2007)
Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5
SJ Mouly et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation
X Zhang et al.
CLINICAL TRANSPLANTATION (2005)
CYP3A5 genotypes and risk of oesophageal cancer in two South African populations
C Dandara et al.
CANCER LETTERS (2005)
Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation
JS McCune et al.
DRUG METABOLISM AND DISPOSITION (2005)
Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage
RA Wilke et al.
PHARMACOGENETICS AND GENOMICS (2005)
Tacrolimus pharmacogenetics: The CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and south Asians
IAM MacPhee et al.
TRANSPLANTATION (2005)
Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients
AN Tucker et al.
CANCER LETTERS (2005)
Cytochrome P450 3A polymorphisms and immunosuppressive drugs
E Thervet et al.
PHARMACOGENOMICS (2005)
Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus
Y Zhao et al.
TRANSPLANTATION PROCEEDINGS (2005)
Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics
M Fröhlich et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states
KS Yu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Lipid-lowering response to statins is affected by CYP3A5 polymorphism
KT Kivistö et al.
PHARMACOGENETICS (2004)
CYP3A variation and the evolution of salt-sensitivity variants
EE Thompson et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2004)
The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation
IAM MacPhee et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels
DA Katz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
In vitro metabolism of cyclosporine A by human kidney CYP3A5
Y Dai et al.
BIOCHEMICAL PHARMACOLOGY (2004)
Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women
MD Floyd et al.
PHARMACOGENETICS (2003)
CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults
RC Givens et al.
JOURNAL OF APPLIED PHYSIOLOGY (2003)
Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups
SJ Lee et al.
PHARMACOGENETICS (2003)
CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations
C Balram et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms
HX Zheng et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2003)
Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes
PS Shih et al.
DRUG METABOLISM AND DISPOSITION (2002)
Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies
JG Blanco et al.
PHARMACOGENETICS (2002)
Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population
M Hiratsuka et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism
YS Lin et al.
MOLECULAR PHARMACOLOGY (2002)
The genetic determinants of the CYP3A5 polymorphism
E Hustert et al.
PHARMACOGENETICS (2001)
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl et al.
NATURE GENETICS (2001)
分享论文
